CNS-targeting pharmacological interventions for the metabolic syndrome.

Abstract

The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.

• Authors: Kerstin Stemmer, Timo D Müller, Richard D DiMarchi, Paul T Pfluger, Matthias H Tschöp
• Journal: The Journal of clinical investigation (J Clin Invest) Vol. 129 Issue 10 Pg. 4058-4071 (08 05 2019) ISSN: 1558-8238 [Electronic] United States
• PMID: 31380808 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Topics

• Animals
• Cardiovascular Diseases (drug therapy, metabolism, pathology)
• Central Nervous System (metabolism, pathology)
• Diabetes Mellitus, Type 2 (drug therapy, metabolism, pathology)
• Drug Delivery Systems
• Dyslipidemias (drug therapy, metabolism, pathology)
• Humans
• Hypertension (drug therapy, metabolism, pathology)
• Metabolic Syndrome (drug therapy, metabolism, pathology)